The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Open accessAbstract
BACKGROUND: Higher intake of marine n-3 (also called omega-3) fatty acids has been associated with reduced risks of cardiovascular disease and cancer in several observational studies. Whether supplementation with n-3 fatty acids has such effects in general populations at usual risk for these end points is unclear. METHODS: (at a dose of 2000 IU per day) and marine n-3 fatty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States. Primary end points were major cardiovascular events (a composite of myocardial infarction, stroke, or death from cardiovascular causes) and invasive cancer of any type. Secondary end points included individual components of the composite cardiovascular end point, the composite end point plus coronary revascularization (expanded composite of cardiovascular events), site-specific cancers, and death from cancer. Safety was also assessed. This article reports the results of the comparison of n-3 fatty acids with placebo. RESULTS: A total of 25,871 participants, including 5106 black participants, underwent randomization. During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24). Invasive cancer was diagnosed in 820 participants in the n-3 group and in 797 in the placebo group (hazard ratio, 1.03; 95% CI, 0.93 to 1.13; P=0.56). In the analyses of key secondary end points, the hazard ratios were as follows: for the expanded composite end point of cardiovascular events, 0.93 (95% CI, 0.82 to 1.04); for total myocardial infarction, 0.72 (95% CI, 0.59 to 0.90); for total stroke, 1.04 (95% CI, 0.83 to 1.31); for death from cardiovascular causes, 0.96 (95% CI, 0.76 to 1.21); and for death from cancer (341 deaths from cancer), 0.97 (95% CI, 0.79 to 1.20). In the analysis of death from any cause (978 deaths overall), the hazard ratio was 1.02 (95% CI, 0.90 to 1.15). No excess risks of bleeding or other serious adverse events were observed. CONCLUSIONS: Supplementation with n-3 fatty acids did not result in a lower incidence of major cardiovascular events or cancer than placebo. (Funded by the National Institutes of Health and others; VITAL ClinicalTrials.gov number, NCT01169259 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“although only REDUCE-IT has shown cardiovascular benefits (as discussed later) (14-17).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“butseverallargeclinicaltrialsfailed to demonstrate any cardiovascular benefit with administration of low doses of omega-3 fatty acids. 8,12,13”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TheVitaminDandOmega-3Trial(VITAL), in which 13% of the participants had type 2 diabetes, supplementation with 1 g of omega-3 fatty acids did not result in a lower incidence of major cardiovascular events (305).”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [305]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials revealed that ω3 PUFA supplementation of <1 g/d resulted in a very limited reduction in atherosclerotic CVD risk of major vascular events and CVD‐caused deaths. 22 , 23 , 133 , 154”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [23]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies showed inconsistent reductions in MACE.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple large studies conducted since then to examine the benefits of low-dose mixtures of EPA and DHA with more contemporary background therapy, including statin therapy, have failed to show any significant reduction in cardiovascular endpoints.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, other recent trials studying lower doses of omega-3 fatty acids in a broader range of patients failed to demonstrate significant reductions of total cardiovascular events. 12,13”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“This may explain why EPA + DHA combination treatment in various trials did not demonstrate an effect on reducing cardiovascular risk. 23 , 24 , 25 , 133”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Earlier trials such as GISSI-Prevenzione, ASCEND, VITAL, and OMEMI evaluated low-dose EPA/DHA mixtures primarily in primary prevention settings or post-MI patients, often without significant baseline TG elevation and with limited use of statins in earlier trials [87–90].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ASCEND (A Study of Cardiovascular Events in Diabetes) [3] and VITAL (Vitamin D and Omega-3 Trial) trials [5] using EPA+DHA did not signi fi cantly reduce the primary cardiovascular endpoints”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“During a median follow-up of 5.3 years, there was no significant difference in the 2 primary endpoints of major cardiovascular events (a composite of MI, stroke, or death from cardiovascular causes) or invasive cancer of any type.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
In the citing paper
“Contemporary studies were conducted with higher standards and consistently failed to demonstrate significant benefits.”
In the citing paper
“at lower doses (1 g/day) these agents have generally failed to show reduced ASCVD.50,51”
From Clinical review on triglycerides (2020) · cites this paper as [51]
In the citing paper
“Recently, a new selective PPAR-α modulator (pemafibrate) has been reported to have marked efficacy in reducing TRLs [317].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [317]
In the citing paper
“However, this trial showed that just 840 mg of combined EPA/DHA significantly reduced MI and major CHD events [63].”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [63]
In the citing paper
“This study did not show that supplementing with n-3 fatty acids reduced the incidence of major CVD events (a composite of MI, stroke, and death from CVD causes) or invasive cancer.”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [63]
In the citing paper
“Individuals with low baseline fish consumption (<1.5 servings/week) had decreased risk for total CV events (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.67 to 0.98).”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“However, there was a 28% reduction in total MI, which emerged after the first year and continued throughout the trial.”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“In the VITAL trial, omega-3 PUFAs did not significantly reduce the primary composite endpoint of major ASCVD events (MI, stroke, and CVD mortality).”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“Black study participants experienced a 77% treatment-associated reduction in MI (HR: 0.23; 95% CI: 0.11 to 0.47), and derived an MI benefit irrespective of baseline fish intake.”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“There were significant reductions in other pre-specified secondary outcomes, including a 17% reduced risk for total coronary heart disease (CHD) and a 50% reduction in fatal MI”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“In the statin era, CVOTs of combination OM-3 fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] have not shown reduction in cardiovascular disease (CVD) events.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“Additional factors that may influence CVOT findings include OM-3 dose, definition of primary composite CV endpoint, and study population.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“The total daily dose of OM-3 was much lower in VITAL and ASCEND (< 1 g/day total OM-3 per each 1-g capsule) than in REDUCE-IT (4 g/day high-purity Rx EPA).”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“The primary composite CV endpoint varied between the studies (Table 1, see footnote); for example, in REDUCE-IT, coronary revascularization and unstable angina were included, in addition to CV death, nonfatal myocardial infarction, and nonfatal stroke.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“A 17% risk reduction was recorded for total coronary heart disease, versus placebo.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“Indeed, while the primary outcome of the study, a reduction in major cardiovascular events (a composite of myocardial infarction, stroke, and death from cardiovascular causes), was not achieved with statistical significance, the analysis did demonstrate an 8% reduction in such events.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“Interestingly for African-Americans, the study found a dramatic 77% reduction in heart attacks linked to daily omega-3 supplementation.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“In people who do not consume the recommended 1 or 2 servings of fish a week, the n-3 LCPUFA supplementation was linked to a 40% reduction in heart attacks; however, among the subjects who followed the fish consumption recommendation, there was no such association.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“The primary conclusion of the VITAL study was not positive regarding the effect of supplementation with n-3 LCPUFA on major cardiovascular events as the data failed to show a lower incidence of major cardiovascular events in the experimental group than in the placebo control group [53].”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“However, the secondary outcomes were highly relevant as omega-3 supplementation was associated with a reduction in total and fatal myocardial infarction risk by 28% and 50%, respectively.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,350
Self-citationPrevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
Third universal definition of myocardial infarction
the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., CHAITMAN, B. R., & White, H. D. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.122 · Cited by 6,585
Isolated Hand Paresis: A Case Series
Alstadhaug, K. B., & Sjulstad, A. S. (2013) · Cerebrovascular Diseases Extra · doi:10.1159/000350708 · Cited by 4,090
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Cited by
Sorted by citations
Items 501–600 of 984
Effects of Vitamin D3 Supplementation on Cardiovascular and Cancer Outcomes by eGFR in VITAL
Limonte, C. P., Zelnick, L. R., Hoofnagle, A. N., Thadhani, R., Melamed, M. L., Mora, S., Cook, N. R., Luttmann‐Gibson, H., Sesso, H. D., Lee, I.-M. M., et al. (2022) · Kidney360 · doi:10.34067/kid.0006472022 · Cited by 10
“3 years and assessed for the primary outcomes of incident major cardiovascular events and invasive cancer.(19,21) Testing for heterogeneity of”
BackgroundSelf-citationLiu, X., Sun, L., Wen, W., Qiu, M., Luo, J., Li, W., Hao, S., He, M., Wu, J., Hu, Y., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1019058 · Cited by 10
Gutiérrez-Pliego, L. E., Martínez-Carrillo, B. E., Reséndiz‐Albor, A. A., & Valdés‐Ramos, R. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200213111452 · Cited by 10
Fatty Acid Mediators in the Tumor Microenvironment
Khadge, S., Sharp, J. G., Thiele, G. M., McGuire, T. R., & Talmadge, J. E. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43093-1_8 · Cited by 11
Block, R., Shearer, G. C., Holub, A. A., Tu, X. M., Mousa, S. A., Brenna, J. T., Harris, W. S., & Tintle, N. (2021) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2021.102283 · Cited by 11
Wyse, J., Mangan, R., & Zgaga, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-90019-7 · Cited by 10
Qin, L., Mei, Y., An, C., Ning, R., & Zhang, H. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109244 · Cited by 10
Fatty Acid Content in Biomasses: State-of-the-Art and Novel Physical Property Estimation Methods
Sousa, A., Andrade, T. A., Errico, M., Coelho, J. P., Filipe, R. M., & Matos, H. A. (2019) · International Journal of Chemical Engineering · doi:10.1155/2019/2430234 · Cited by 10
“Fatty acids are characterized by an outstanding range of applications within the energy domain, such as biofuels [8], and flow improvers for crude oils [9–12], or within other high end industries such as food supplements [13], cosmetics [14], medicines, and drugs [15, 16].”
BackgroundInfluence of different heat treatments on the lipid quality of African Catfish (Clarias gariepinus)
Domiszewski, Z., Duszyńska, K., & Stachowska, E. (2020) · Journal of Aquatic Food Product Technology · doi:10.1080/10498850.2020.1817219 · Cited by 10
Algal Derived Functional Lipids and their Role in Promoting Health
Terme, N., Chénais, B., Fournière, M., Bourgougnon, N., & Bedoux, G. (2021) · Wiley eBooks · doi:10.1002/9781119542650.ch13 · Cited by 10
Omega-3 Fatty Acids and Risk for Atrial Fibrillation
Ballantyne, C. M., & Jia, X. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.026 · Cited by 10
Tikkanen, J. T., Soliman, E. Z., Pester, J., Danik, J. S., Gomelskya, N., Copeland, T., Lee, I.-M. M., Buring, J. E., Manson, J. E., Cook, N. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38344-x · Cited by 9
Self-citationWimalawansa, S. J. (2025) · Nutrients · doi:10.3390/nu17030599 · Cited by 9
Li, G., Liu, B., Yang, H., Zhang, D., Wang, S., Zhang, Z., Zhao, Z., Zhang, Y., Zhou, H., & Wang, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114454 · Cited by 9
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 42
Schooling, C. M., Kwok, M. K., & Zhao, J. V. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad108 · Cited by 10
Bakbak, E., Krishnaraj, A., Bhatt, D. L., Quan, A., Park, B., Bakbak, A. I., Bari, B., Terenzi, K. A., Pan, Y., Fry, E. J., et al. (2024) · Med · doi:10.1016/j.medj.2024.03.009 · Cited by 10
Diet and Nutrition: Implications to Cardiometabolic Health
Johnson, M. (2019) · Journal of Cardiology and Cardiovascular Sciences · doi:10.29245/2578-3025/2019/2.1168 · Cited by 9
Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020
Mosca, L. J., Návar, A. M., & WENGER, N. K. (2020) · Journal of Women s Health · doi:10.1089/jwh.2019.8189 · Cited by 9
“The most recent combination omega-3 fatty acid outcome trial, the Vitamin D and Omega-3 Trial (VITAL) (N = 25,871; 51% women), randomized patients in a factorial design to receive a low dose (1 g/day) of DHA+EPA, vitamin D3 (200 IU) supplementation, or placebo.(7,56) After 5.”
BackgroundKim, J., Hoang, T., Kim, J., Bu, S. Y., Choi, J., Park, E., Lee, S.-M., Park, E., Min, J. Y., Lee, I. S., et al. (2020) · Nutrients · doi:10.3390/nu12103203 · Cited by 10
Self-citationSpeciesism, Science, and Society
Swartz, B., & Mishler, B. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-99031-2_1 · Cited by 8
Metabolomic landscape of overall and common cancers in the UK Biobank: A prospective cohort study
Hu, C., Fan, Y., Lin, Z., Xie, X., Huang, S., & Hu, Z. (2024) · International Journal of Cancer · doi:10.1002/ijc.34884 · Cited by 10
“30 However, a randomized controlled trial 31 showed that supplementation with Omega-3 did not result in a lower incidence of cancer than a placebo.”
BackgroundRelationship between Polyunsaturated Fatty Acid Metabolism and Atherosclerosis
Liu, Q., Liu, Z., Wu, D., & Wang, S. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504142 · Cited by 8
Assadourian, J. N., Peterson, E. D., Gupta, A., & Návar, A. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033748 · Cited by 8
Wang, Z., Yang, Y., Tang, F., & Wu, M. (2024) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2024.102615 · Cited by 9
Understanding the Role of Polyunsaturated Fatty Acids in the Development and Prevention of Cancer
Akbar, S., Rahman, A., Aḥmad, N., Imran, M., & Hafeez, Z. (2024) · Cancer treatment and research · doi:10.1007/978-3-031-55622-7_3 · Cited by 8
Ciobotaru, R., Tas, A. A., & Khan, T. A. (2024) · Foods · doi:10.3390/foods13213346 · Cited by 9
Dong, S., Wang, Y., Bian, J., Chen, H., Dong, J., Zhu, J., Zhang, T., Du, Q., & Zhao, R. (2024) · Nutrition Journal · doi:10.1186/s12937-024-01051-y · Cited by 9
New Approaches to Lipoproteins for the Prevention of Cardiovascular Events
Fujino, M., Giovanni, G. D., & Nicholls, S. J. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22031 · Cited by 8
“Similarly, the VITAL trial, which enrolled 25,871 participants for primary prevention, showed no significant impact on the major CV composite endpoints with the administration of 1 g of marine omega-3 fatty acids per day 64) .”
Dietary Supplement Safety in Older Adults: A Review of Published Case Reports
Shahverdian, A., & Jafari, M. (2025) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2025.32 · Cited by 8
Molecular breeding of pigs in the genome editing era
Chen, J., Wang, J., Zhao, H., Tan, X., Yan, S., Zhang, H., Wang, T., & Tang, X. (2025) · Genetics Selection Evolution · doi:10.1186/s12711-025-00961-7 · Cited by 8
Peterson, A. L. H., Ashraf, A. P., Bachman, J., Hegele, R. A., Rashad, M., South, A. M., Tran, A. H., Zachariah, J. P. V., & Wong, J. P. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000195 · Cited by 8
Polyunsaturated Fatty Acids: Impact on Health and Disease Status
Akbar, S., Bhatti, M. Z., Saeed, R. F., & Qazi, A. S. (2021) · Life and Science · doi:10.37185/lns.1.1.85 · Cited by 8
Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists
Patel, D. K., & Busch, R. S. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211023715 · Cited by 9
“The Vitamin D and Omega-3 Trial (VITAL) was a primary prevention trial evaluating the use of 840 mg/day EPAþDHA with or without vitamin D in healthy patients with no baseline CV disease.(31) The study demonstrated no significant difference in rates of MI, stroke, or CV death versus placebo during a median follow-up of…”
BackgroundMethodInfluentialZhou, J. S., Tan, X., Li, Y., Wan, R., Wu, Z., Lin, Z., Wang, W., Luo, Y., & Liu, T. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-023-04097-4 · Cited by 10
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9
Polyunsaturated Fatty Acids in Quinoa Induce Ferroptosis of Colon Cancer by Suppressing Stemness
Li, S., Ding, M., Feng, M., Fan, X., & Li, Z. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c00118 · Cited by 8
Management of dyslipidaemias in the elderly population—A narrative review
Anagnostis, P. G., Vaitsi, K., Veneti, S., Georgiou, T., Paschou, S. Α., Lambrinoudaki, I. V., & Goulis, D. G. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.03.011 · Cited by 8
Haidari, F., Abiri, B., Iravani, M., Razavi, S. M., Sarbakhsh, P., Angali, K. A., & Vafa, M. (2019) · Trials · doi:10.1186/s13063-019-3719-3 · Cited by 8
The Rise and Fall “ing” of the HDL Hypothesis
Feghaly, J., & Mooradian, A. D. (2020) · Drugs · doi:10.1007/s40265-020-01265-4 · Cited by 8
Hype um die Vitamin-D-Substitution: Was bleibt?
Bischoff-Ferrari, H. A. (2020) · Der Internist · doi:10.1007/s00108-020-00869-y · Cited by 8
“1 Relevante StudienzurVitamin-D-GabemitundohneKalziumbezüglichderFrakturprävention sowieKrebs-undkardiovaskulärenResulateder VITAL Studie Autor Intervention Zielpopulation und Einschränkungen Methoden Resultate Frakturprävention bei Erwachsenen 50+ Weaver et al. (2016, [26]) 8 RCT (n= 30.970) Kombinierter Effekt von V…”
BackgroundInfluentialNicholls, S. J., & Nelson, A. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000712 · Cited by 8
“The Vitamin D and Omega-3 Trial (VITAL) was a two-by-two factorial design, placebo-controlled study, which evaluated the impact of administration of vitamin D or omega-3 fatty acids in men at least 50 or women at least 55 years of age and without clinically manifest cardiovascular disease or cancer [10].”
BackgroundInnovation in the design of large-scale hybrid randomized clinical trials
Rist, P. M., Sesso, H. D., & Manson, J. E. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106178 · Cited by 8
Self-citationFabian, C. J., Befort, C. A., Phillips, T. A., Nydegger, J. L., Kreutzjans, A. L., Powers, K. R., Metheny, T., Klemp, J. R., Carlson, S. E., Sullivan, D. K., et al. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0656 · Cited by 8
“The VITAL trial using one fourth of the dose of combined EPA þ DHA esters we employed did not show evidence of prevention of cancer or cardiovascular disease (49).”
Batista, E. S., Rios, T. D. S., Muñoz, V. R., de Jesus, J. S., Vasconcelos, M. M., da Cunha, D. T., Marques-Rocha, J. L., Nakandakari, S. C. B. R., Lara, R., da Silva, A. S. R., et al. (2021) · Trials · doi:10.1186/s13063-021-05702-x · Cited by 8
“mary prevention (myocardial infarction, stroke, and cardiovascular mortality) [29].”
BackgroundApproach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 8
Signaling through Free Fatty Acid Receptor 4 Attenuates Cardiometabolic Disease
O’Connell, T. D., Murphy, K. A., Zhang, N., Puccini, S. J., Healy, C. L., Harsch, B. A., Zhang, M. J., & Shearer, G. C. (2022) · Physiology · doi:10.1152/physiol.00007.2022 · Cited by 9
Accinni, T., Panfili, M., Tarsitani, L., Biondi, M., Pasquini, M., & Maraone, A. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/3801235 · Cited by 8
Assessing the Highest Level of Evidence from Randomized Controlled Trials in Omega-3 Research
Sahye‐Pudaruth, S., & David, W. L. (2023) · Nutrients · doi:10.3390/nu15041001 · Cited by 9
“84 g EPA + DHA with 2000 IU of vitamin D daily for more than 5 years also reported no significant reduction in major cardiovascular events or mortality [30].”
BackgroundMoyad, M. A. (2020) · Current Urology Reports · doi:10.1007/s11934-020-0967-4 · Cited by 7
Li, Y., Jia, Z., & Zhu, H. (2019) · doi:10.20455/ros.2019.817 · Cited by 8
Omega-3 polyunsaturated fatty acids: is their future VITALized or REDUCEd?
Gajos, G. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz081 · Cited by 8
El‐Bayoumy, K., & Manni, A. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1651348 · Cited by 9
“The Placebo Compound Used as a Comparator The use of a “beneficial” placebo such as olive oil (17) as opposed to an “inert” compound such as capric acid or caprylic acid (18) or a placebo with an adverse profile such as mineral oil (19) could account in part CONTACT Karam El-Bayoumy kee2@psu.edu Department of Biochemi…”
BackgroundPicard, F. A., & Steg, P. G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00919-2 · Cited by 8
Chandra, A., Røsjø, H. R., Eide, I. A., Vigen, T., Ihle‐Hansen, H., Orstad, E. B., Rønning, O. M., Lyngbakken, M. N., Berge, T., Schmidt, E. B., et al. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02007-3 · Cited by 8
Qian, F., Guo, Y., Li, C., Liu, Y., Luttmann‐Gibson, H., Gomelskaya, N., Demler, O., Cook, N. R., Lee, I.-M. M., Buring, J. E., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02470-1 · Cited by 8
“N-3 FA may reduce the risk of CVD, particularly CHD, as shown in observational studies of fish/omega-3 intake and biomarkers [15, 16], as well as some RCTs of marine omega-3 fatty acid supplementation [17–19].”
BackgroundInfluentialSelf-citationBlomquist, S. A., Albrecht, J. H., Hallmark, B., Klimentidis, Y. C., García, L. A., Mandarino, L. J., Coletta, D. K., & Chilton, F. H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1538505 · Cited by 9
“This question is especially relevant given findings from recent notable n-3 HUFA supplementation randomized controlled trials such as ASCEND, VITAL, and REDUCE-IT (69–71).”
Khabir, Z., Abdelhafez, A., Camponovo, F. F., Joyce, P., & Garcia‐Bennett, A. E. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2615693 · Cited by 9
Serum Levels of Free Fatty Acids in Obese Mice and Their Associations with Routine Lipid Profiles
Sun, S. Y., Yang, W. Y., Tan, Z., Zhang, X. Y., Shen, Y. L., Guo, Q. W., Su, G. M., Chen, X., Lin, J., & Fang, D. Z. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s348800 · Cited by 7
We are what we eat: The role of lipids in metabolic diseases
Berná, G., López-Bermudo, L., Escudero‐López, B., & Martı́n, F. (2023) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2022.11.004 · Cited by 8
Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study
Mafham, M. M., Bowman, L. J., Haynes, R., & Armitage, J. (2019) · Diabetologia · doi:10.1007/s00125-019-05049-8 · Cited by 6
“Study (year completed) BDS 1988 [18] PHS 1989 [19] WHS 2005 [17] WACS 2007 [20] ASCEND 2017 [14,15] VITAL 2018 [21]”
The return of triglycerides and revival of omega-3 fatty acids!
Ferrières, J. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.04.004 · Cited by 7
Efficacy of Biologically Active Food Supplements for People with Atherosclerotic Vascular Changes
Pleshkova, N., Tokhiriyon, B., Алексеевич, В. А., Poznyakovsky, V. M., Lapina, V., Takaeva, M. A., Sorokopudov, V. N., & Karanina, E. V. (2022) · Molecules · doi:10.3390/molecules27154812 · Cited by 7
Xu, Q., Du, L., Gu, H., Ji, M., & Zhan, L. (2022) · Nutrición Hospitalaria · doi:10.20960/nh.04148 · Cited by 8
A stepwise approach to prescribing novel lipid-lowering medications
Kakavand, H., Aghakouchakzadeh, M., Shahi, A., Virani, S. S., Dixon, D. L., Tassell, B. W. V., & Talasaz, A. H. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.003 · Cited by 7
Bork, C. S., Lundbye‐Christensen, S., Venø, S. K., Lasota, A. N., Tjønneland, A. M., Schmidt, E. B., & Overvad, K. (2023) · European Journal of Nutrition · doi:10.1007/s00394-022-03081-w · Cited by 7
Lu, L. W., Quek, S. Y., Lu, S.-P., & Chen, J. (2023) · Metabolites · doi:10.3390/metabo13050630 · Cited by 7
“2019 VITAL [110] American 25,871 >50 (males) >55 (females) 49.”
BackgroundInfluentialMarine Biotechnology and Its Applications in Drug Discovery
Sankarapandian, V., Jothirajan, B., Arasu, S. P., Subramaniam, S., & Maran, B. A. V. (2023) · Springer eBooks · doi:10.1007/978-981-99-0624-6_9 · Cited by 8
Liu, X., Li, Y., Wan, X., Zhuang, P., Wu, Y., Zhang, L., Yang, A., Yao, J., Zhang, Y., & Jiao, J. (2023) · Nutrients · doi:10.3390/nu15143176 · Cited by 7
“Supplementation with n-3 PUFA protected against major cardiovascular events and myocardial infarction in individuals with low intake fish intake but not in those with higher intake in the VITAL trial [35].”
BackgroundOmega‐3 fatty acids and cardiovascular prevention: is the jury still out?
Hamilton-Craig, C. R., Kostner, K., Colquhoun, D., & Nicholls, S. J. (2023) · Internal Medicine Journal · doi:10.1111/imj.16283 · Cited by 8
Bioactive Lipids as Mediators of the Beneficial Actions of Statins
Das, U. N. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000689 · Cited by 7
Survey of the erythrocyte EPA+DHA levels in the heart attack/stroke belt
Harris, W. S., Jackson, K. H., Brenna, J. T., Rodriguez, J. C., Tintle, N., & Cornish, L. (2019) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2019.07.010 · Cited by 7
Optimal Dose of n-3 Polyunsaturated Fatty Acids for Cardiovascular Event Prevention
Nishizaki, Y., & Daida, H. (2020) · Circulation Reports · doi:10.1253/circrep.cr-20-0012 · Cited by 7
Fish in the Mediterranean diet
Molina‐Vega, M., Gómez‐Pérez, A. M., & Tinahones, F. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818649-7.00025-4 · Cited by 11
Higher omega-3 index is associated with more rapid heart rate recovery in healthy men and women
Farrell, S. W., DeFina, L. F., Tintle, N., Barlow, C. E., Leonard, D. S., Haskell, W. L., Berry, J. D., Willis, B. L., Pavlovic, A., & Harris, W. S. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102206 · Cited by 8
Diet and prostate health: an underrated tool?
Vignera, S. L., & Basile, L. (2022) · The Aging Male · doi:10.1080/13685538.2022.2044468 · Cited by 7
Miller, M. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001136 · Cited by 7
“1 g daily) without reduction in CVD events [14,15].”
BackgroundProfiles of volatiles in microalgae depend on the extraction and analytical methods
de Carvalho, C. C. C. R., Neves, K., de Almeida, S. V. T. F., Steinrücken, P., & Kleinegris, D. M. M. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1589776 · Cited by 7
Roger, G., Packard, C. J., Masana, L., Laufs, U., Catapano, A. L., & Steg, P. G. (2025) · Heart · doi:10.1136/heartjnl-2025-325765 · Cited by 6
Zuo, X., Kiyasu, Y., Liu, Y., Deguchi, Y., Liu, F., Moussalli, M. J., Tan, L., Wei, B., Wei, D., Yang, P., et al. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101607 · Cited by 9
Amedei, A., Lamminpää, I., & Parolini, C. (2025) · Biomedicines · doi:10.3390/biomedicines13102428 · Cited by 6
“OM3 [106], ORIGIN [107], Risk and Prevention study [108], ASCEND [109], VITAL [110], STRENGTH [8], and OMEMI [111], who found no significant difference in the primary outcome compared to the placebo.”
Nieto, Á. A. V., Díaz, A. H., Millán, M. H., & Sagredo, D. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf201 · Cited by 9
Toth, P. P., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/216960 · Cited by 7
“…Events in Diabetes) [71], STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia) [72], OMEMI (Omega-3 fatty acids in Elderly with Myocardial Infarction) [73] and VITAL (Vitamin D and Omega-3 Trial) trials [74].”
Jones, P. J. H., & Lichtenstein, A. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-66162-1.00004-4 · Cited by 8
Gehr, N. L., Karlsson, P., Timm, S., Christensen, S., Hvid, C. A., Peric, J., Hansen, T. F., Lauritzen, L., Finnerup, N. B., & Ventzel, L. (2024) · BMC Cancer · doi:10.1186/s12885-024-11856-z · Cited by 6
Eicosapentaenoic acid and docosahexaenoic acid suppress colonic tumorigenesis in obese mice
Xu, Y., Zhang, H., Yang, H., Liu, C., Song, C., Cheng, Y., He, C., Zou, Z., Zhou, D., Wu, G., et al. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106164 · Cited by 6
Liu, C., & Zhang, Z. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf006 · Cited by 6
Label Statements and Perceived Health Benefits of Dietary Supplements
Assadourian, J. N., Peterson, E. D., & Návar, A. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.33118 · Cited by 7
Benefits and harms of wellness initiatives
Fiala, C., Taher, J., & Diamandis, E. P. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0122 · Cited by 6
Fish, Cardiovascular Disease, and Mortality—What Is the Global Evidence?
Mozaffarian, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.0045 · Cited by 7
Adipose tissue macrophages and atherogenesis – a synergy with cholesterolaemia
Poledne, R., & Lesná, I. K. (2021) · Physiological Research · doi:10.33549/physiolres.934745 · Cited by 6
Revisiting cardiovascular risk reduction in type 2 diabetes and dyslipidemia
Lim, P., & Bleich, D. (2022) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2022.200141 · Cited by 7
Big Fish or No Fish; Eicosapentaenoic Acid and Cardiovascular Disease
Goldberg, I. J., Gjini, J., & Fisher, E. A. A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.012 · Cited by 6
Brasky, T. M., Hade, E. M., Cohn, D. E., Newton, A. M., Petruzella, S., O’Connell, K., Bertrand, K. A., Cook, L. S., Vivo, I. D., Du, M., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.10.015 · Cited by 6
Impact of Dietary Fats on Cardiovascular Disease with a Specific Focus on Omega-3 Fatty Acids
Maggioni, A. P., Poli, G., & Mannucci, P. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226652 · Cited by 6
Mehdawi, A., Mohammad, B. A., Mosleh, I. M., Khader, H. A., Habash, M., Nassar, R. I., Awwad, S. H., Hasoun, L., & Abu‐Samak, M. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001398 · Cited by 7
Tinagli, S., Amarie, R. E., Conte, G., Tognocchi, M., Mele, M. L., Mantino, A., Casarosa, L., & Serra, A. (2023) · Foods · doi:10.3390/foods12040718 · Cited by 6
Wang, Z., Zhang, X., Qu, Y., Zhang, S., Chen, Y., Chen, X., Qi, X., Liu, P., Liu, S., Jiang, S., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01838-8 · Cited by 7
Gupta, A., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113758 · Cited by 7
“The primary endpoint of cardiovascular death, myocardial infarction, stroke or revascularisation was comparable between patients receiving omega-3 PUFAs and placebo [61,62,64,65].”
BackgroundInfluentialDevelopment of snacks based on Macadamia integrifolia nuts enriched with omega-3
Lamas, D. L., & Alvarez, S. (2023) · Food Chemistry Advances · doi:10.1016/j.focha.2023.100564 · Cited by 6
Metadata
- Authors
- Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., D’Agostino, D., Friedenberg, G., Ridge, C., Bubes, V., Giovannucci, E. L., Willett, W. C., & Buring, J. E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (J.E.M., N.R.C., I-M.L., W.C., S.S.B., S.M., H.G., C.M.A., D.G., T.C., D.D., G.F., C.R., V.B., E.L.G., W.C.W., J.E.B.), and the Departments of Epidemiology (J.E.M., N.R.C., I.-M.L., W.C.W., J.E.B.) and Nutrition (E.L.G., W.C.W.), Harvard T.H. Chan School of Public Health — all in Boston.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 23-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6392053
- OpenAlex
- W2899720772
- Semantic Scholar
- bb3183c85d8686140abdf23d14174712153d2ed2
- Cited by
- 979
- References
- 94
- Citations by year
- 2026: 78 · 2025: 93 · 2024: 98 · 2023: 121 · 2022: 130 · 2021: 136 · 2020: 162 · 2019: 141
- FWCI
- 94.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R0 CA138962)
- National Cancer Institute
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
- Keywords
- omega-3 fatty acids, cardiovascular disease prevention, cancer prevention, primary prevention, cardiovascular events, myocardial infarction, stroke, cancer mortality, coronary revascularization, dietary supplementation, cardiovascular risk reduction, cancer risk reduction, older adults, Black participants, cancer risk factors
- MeSH terms
- Aged, Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms, Fatty Acids, Omega-3, Incidence, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
